Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214727) titled 'A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease' on Oct. 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Alnylam Pharmaceuticals
Condition:
Alzheimer's Disease
Intervention:
Drug: ALN-5288
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 9, 2025
Target Sample Size: 50
Countries of Recruitment:
Canada
Netherlands
Spain
United Kingdom
Canada
Netherlands
Spain
United Kingdom
To know more, ...